The earnings call highlighted significant progress in the HCV program with promising clinical trial results and a strong financial position. However, challenges include regulatory delays in non-North American markets and the ongoing high rates of HCV infections. Overall, the positive advancements and strong market interest suggest a promising outlook.

Company Guidance -

Q3 2025

During the Atea Pharmaceuticals' Second Quarter 2025 Earnings Conference Call, significant progress was highlighted in their HCV program, particularly the commencement of patient dosing in the global Phase III trials, C-BEYOND and C-FORWARD, anticipated to yield top-line results by mid-2026 and end-2026, respectively. The company's Phase II trial demonstrated a 98% cure rate in the primary efficacy analysis with an 8-week treatment regimen, showcasing robust potency across HCV genotypes. Financially, Atea reported $379.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, projecting their cash runway through 2027. Additionally, a stock repurchase of up to $25 million was announced, alongside the appointment of Dr. Howard Berman as a new independent director. The company aims to disrupt the approximately $3 billion global HCV market with their potential best-in-class regimen, leveraging a differentiated profile that addresses the needs of modern HCV patients.

Progress in HCV Program

Initiated dosing patients in global Phase III development program for HCV treatment with bemnifosbuvir and ruzasvir. Phase II trial results demonstrated a 98% cure rate with an 8-week treatment.

Strong Financial Position

Reported $379.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, with a cash runway expected to extend through 2027.

Phase I Study Results

Phase I studies showed low risk of drug-drug interactions, supporting use in HCV patients co-infected with HIV.

Market Research Findings

Quantitative study revealed 76% of top U.S. DAA prescribers are extremely likely to prescribe the BEM/RZR regimen, indicating high preference.

Stock Repurchase Program

Announced repurchase of up to $25 million of company stock, reflecting commitment to return capital to shareholders.

Atea Pharmaceuticals (AVIR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AVIR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.41 / -	-0.37	―	―	―
Aug 07, 2025	2025 (Q2)	-0.41 / -0.44	-0.48	8.33% (+0.04)
May 12, 2025	2025 (Q1)	-0.50 / -0.40	-0.75	46.67% (+0.35)	―	―
Mar 06, 2025	2024 (Q4)	-0.29 / -0.40	-0.47	14.89% (+0.07)
Nov 07, 2024	2024 (Q3)	-0.43 / -0.37	-0.4	7.50% (+0.03)
Aug 07, 2024	2024 (Q2)	-0.66 / -0.48	-0.34	-41.18% (-0.14)
May 14, 2024	2024 (Q1)	-0.52 / -0.75	-0.43	-74.42% (-0.32)
Feb 28, 2024	2023 (Q4)	-0.43 / -0.47	-0.41	-14.63% (-0.06)
Nov 08, 2023	2023 (Q3)	-0.46 / -0.40	-0.1	-300.00% (-0.30)
Aug 08, 2023	2023 (Q2)	-0.47 / -0.34	-0.38	10.53% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AVIR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$3.46	$3.38	-2.31%
May 12, 2025	$2.96	$2.63	-11.15%
Mar 06, 2025	$3.00	$2.99	-0.33%
Nov 07, 2024	$3.44	$3.50	+1.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Atea Pharmaceuticals (AVIR) report earnings?

Atea Pharmaceuticals (AVIR) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Atea Pharmaceuticals (AVIR) earnings time?

Atea Pharmaceuticals (AVIR) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AVIR EPS forecast?

AVIR EPS forecast for the fiscal quarter 2025 (Q3) is -0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing